In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Set Alert for Articles By Ramsey Baghdadi

Latest From Ramsey Baghdadi

For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review

For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.

Pricing Debate Medicare

CAR-T Coverage: CMS Takes Gradual Approach With Eye Toward New Entrants, Indications

As final decision looms, initial move to hold off on DRG but increase payment for CAR-T therapies shows CMS taking a slow and steady approach to paying for the products.

Reimbursement Cancer

Biopharma’s ACA Invalidation Chaos: Biosimilars Are Just The Beginning

List of biopharma provisions at risk if the ACA is invalidated is long and the impact of each one is difficult to predict. 
Biosimilars Politics

Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS

Jatenzo clears US FDA 15 months after second negative advisory committee review. 
Approvals Drug Safety

Trump’s Big Missed Opportunity: Medicare For All

With control over all branches of government, President Trump and Republicans made a choice to pursue repeal of the ACA and tax cuts over a strategy that could have redefined the party: Medicare For All with competitive private sector principles. 
Pricing Debate Legislation

HHS Senior Advisor O’Brien Emerges As Azar’s Lead On Drug Pricing In 2019

O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.
Pricing Debate Policy
See All